.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Gastrointestinal Pipeline Drugs

February 23, 2011

Credits: 1.0 contact hours (0.10 CEUs)

Michael Marlan Mohundro, PharmD, Director of Pharmacy, Our Lady of the Lake Regional Medical Center

Brice Labruzzo Mohundro, PharmD, Assistant Professor, University of Louisiana at Monroe College of Pharmacy—Baton Rouge Campus

Educational Objectives

After completing this activity, participants should be able to:

Identify and compare mechanisms of action, safety, tolerability, and efficacy profiles of emerging therapies for common gastrointestinal (GI) disorders
Recognize the roles of emerging therapies for the treatment of specific GI disorders

Target Audience: This activity is intended for pharmacists—in the community, health systems, or other environments—who treat patients with GI disorders, or any healthcare practitioners who are interested in the availability of new drugs to treat GI disorders.